We are live on ! Find out more
STLN

Starling Oncology Institute, Inc. Common Stock
STLN

39 hedge funds and large institutions have $8.83M invested in Starling Oncology Institute, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 13 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.72% more ownership

Funds ownership: 23.4% → 25.12% (+1.7%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

17% less funds holding

Funds holding: 47 → 39 (-8)

31% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 13

67% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 12

69% less capital invested

Capital invested by funds: $28.2M → $8.83M (-$19.4M)

Holders
39
Holders Change
-8
Holders Change %
-17.02%
% of All Funds
0.56%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
4
Increased
9
Reduced
13
Closed
12
Calls
$39K
Puts
–
Net Calls
+$39K
Net Calls Change
+$39K

Top Buyers

Rank Fund Capital Flow
1
TAS
TIFF Advisory Services
Pennsylvania
+$849K
2
KLC
Kent Lake Capital
Nevada
+$481K
3
Citadel Advisors
Citadel Advisors
Florida
+$204K
4
Renaissance Technologies
Renaissance Technologies
New York
+$170K
5
BlackRock
BlackRock
New York
+$47.3K

Top Sellers

Rank Fund Capital Flow
1
KMC
Kirr Marbach & Co
Indiana
-$331K
2
EPA
Element Pointe Advisors
Florida
-$314K
3
Squarepoint
Squarepoint
New York
-$167K
4
TM
Triatomic Management
California
-$69.8K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$60K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$2.19M -$1.84K -2,159 -0%
DM
2
Deerfield Management
New York
$1.55M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$820K – – –
KLC
4
Kent Lake Capital
Nevada
$805K +$481K +563,287 +47%
Balyasny Asset Management
5
Balyasny Asset Management
Illinois
$794K – – –
TAS
6
TIFF Advisory Services
Pennsylvania
$653K +$849K +995,280 +235%
TM
7
Triatomic Management
California
$369K -$69.8K -81,724 -9%
CI
8
Cincinnati Insurance
Ohio
$322K – – –
BFM
9
Boston Financial Management
Massachusetts
$231K -$3.92K -4,588 -62%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$166K +$5.26K +6,166 +2%
Renaissance Technologies
11
Renaissance Technologies
New York
$156K +$170K +199,300 +142%
Citadel Advisors
12
Citadel Advisors
Florida
$124K +$204K +239,558 +795%
FCM
13
FourWorld Capital Management
New York
$118K +$5.67K +6,641 +3%
BlackRock
14
BlackRock
New York
$94.2K +$47.3K +55,383 +37%
FL
15
FreeGulliver LLC
Louisiana
$86.6K – – –
Millennium Management
16
Millennium Management
New York
$50.2K -$33.3K -39,057 -26%
State Street
17
State Street
Massachusetts
$46.6K – – –
SCM
18
Saba Capital Management
New York
$43.4K – – –
FCG
19
Fielder Capital Group
Tennessee
$32.3K – – –
Northern Trust
20
Northern Trust
Illinois
$29.9K -$80 -94 -0.1%
QFA
21
Quattro Financial Advisors
Texas
$25.7K – – –
Bank of New York Mellon
22
Bank of New York Mellon
New York
$20.7K – – –
Jane Street
23
Jane Street
New York
$14.5K +$27K +31,611 New
Susquehanna International Group
24
Susquehanna International Group
Pennsylvania
$14.3K +$26.6K +31,182 New
Morgan Stanley
25
Morgan Stanley
New York
$13.5K -$35.2K -41,214 -58%
1
2 3

STLN Hedge Fund Activity: Q2 2024 in Review

39 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Starling Oncology Institute, Inc. Common Stock (STLN) for Q2 2024, worth a combined $8.83M — down 69% from $28.2M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of STLN and 4 opened new positions — a net loss of 8 holders — while 13 trimmed existing stakes and 9 added.

The largest buyer was TIFF Advisory Services, adding an estimated $849K. The largest seller was Kirr Marbach & Co, exiting entirely with an estimated $331K sold.

  • 39 institutional investors held Starling Oncology Institute, Inc. Common Stock (STLN) as of Q2 2024, down from 47 in Q1 2024.
  • Funds reported $8.83M of Starling Oncology Institute, Inc. Common Stock stock for Q2 2024, down 69% quarter-over-quarter.
  • 4 funds opened new Starling Oncology Institute, Inc. Common Stock positions in Q2 2024 and 12 closed out, a net change of -8 holders.
  • The largest Starling Oncology Institute, Inc. Common Stock buyer in Q2 2024 was TIFF Advisory Services, an estimated $849K added.
  • The largest Starling Oncology Institute, Inc. Common Stock seller in Q2 2024 was Kirr Marbach & Co, an estimated $331K sold.

Based on aggregated 13F filings for Q2 2024.